Komori
Immuno-Biological Laboratories (4570) · RiskRestated

Risk of Intellectual-Property Infringement and Litigation

First written in FY2016. 3 of 4 entries say "Restated". Latest entry: FY2020.

4entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY20202016: 120162017: 120172018: 020182019: 120192020: 12020
Same theme, other companies
Risk of Infringing Third-Party Intellectual Property RightsA theme 465 companies write about · 468 as a headwind · 1 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 197 companies compared. The sentences above are computed from all 197.Comparing 200 of the theme's 469 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2020RestatedAnnual report

    「As these risks are expected to increase as the business expands, we plan to further strengthen our management framework for intellectual property rights.」

    Continues to identify the risks of intellectual property infringement and litigation, along with responses through license agreements and other measures and the policy of strengthening the management framework.
  2. FY2019RestatedAnnual report

    「The Group plans to further strengthen its management framework for intellectual property rights. However, if a lawsuit is filed, it could have a material impact on the Group's business strategy and operating results.」

    While stating that there are currently no intellectual property infringement lawsuits, continues to identify the risks associated with business expansion and the policy of strengthening the management framework.
  3. FY2017RestatedAnnual report

    「Because the Group has promptly entered into license agreements whenever it has discovered that its activities could infringe the intellectual property rights of others, it has never been sued for infringement of intellectual property rights. However, such risks are expected to increase as the business expands.」

    While stating that there have been no intellectual property infringement lawsuits, restates the expected increase in risk as the business expands and the policy of strengthening the management framework.
  4. FY2016First statedAnnual report

    「Because the Group has promptly entered into license agreements whenever it has discovered that its activities could infringe the intellectual property rights of others, it has never been sued for infringement of intellectual property rights. However, such risks are expected to increase as the business expands.」

    While stating that no lawsuits have been filed at present, anticipates increased intellectual property risks as the business expands.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Immuno-Biological Laboratories yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of Intellectual-Property Infringement and Litigation | Immuno-Biological Laboratories Co.,Ltd. (4570) | Komori